IP Library › Granted Patent US 7,319,088
Granted Patent B2
US 7,319,088 · App. 11/035,296 · Granted Jan 15, 2008

Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof

Assignee: Vicuron Pharmaceuticals Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,319,088
App. No.
11/035,296
Granted
Jan 15, 2008
Kind
B2
Abstract

The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated antibiotic 107891 which is produced by fermentation of Microbispora sp. ATCC PTA-5024, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes. Antibiotic 107891, which is a complex comprising two Factors, denominated Factors A1 and A2, has a peptide structure containing lanthionine and methyllanthionine as constituents which are typical characteristics of the antibiotics of the lantibiotics group. Antibiotic 107891 and its Factors A1 and A2 show a good antibacterial activity against Gram-positive bacteria including methicillin resistant and vancomycin resistant strains, and is active also against some Gram-negative bacteria such as M. catharralis, Neisseria species and H. influenzae and Mycobacteria.

Claims (10)

1. A compound isolated from Microbispora sp. ATCC PTA-5024 of the formula

wherein X is selected from the group consisting of F, Cl, Br, and I; and

wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are independently selected from the group consisting of H, and OH, or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein R 4 , R 5 , R 6 , R 7 , and R 8 are H.

3. The compound of claim 2 , wherein R 1 is H, R 2 is H, and R 3 is H.

4. The compound of claim 2 , wherein R 1 is H, R 2 is H, and R 3 is OH.

5. The compound of claim 2 , wherein R 1 is H, R 2 is OH, and R 3 is OH.

6. The compound of claim 2 , wherein R 1 is OH, R 2 is OH, and R 3 is OH.

7. The compound of claim 2 , wherein R 1 is OH, R 2 is H, and R 3 is H.

8. The compound of claim 2 , wherein R 1 is OH, R 2 is H, and R 3 is OH.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2014
From: SENTINELLA PHARMACEUTICALS, INC.
To: NAICONS SRL
Reel/Frame 034578/0356 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2012
From: LAZZARINI, AMERIGA; GASTALDO, LUCIANO; CANDIANI, GIANPAOLO; CICILIATO, ISMAELA; LOSI, DANIELE; MARINELLI, FLAVIA; SELVA, ENRICO; PARENTI, FRANCO
To: VICURON PHARMACEUTICALS INC.
Reel/Frame 028161/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2011
From: NAICONS S.C.A.R.L.
To: NEXTHERA BIOSCIENCES S.R.L.
Reel/Frame 026337/0188 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2011
From: NEXTHERA BIOSCIENCES S.R.L.
To: SENTINELLA PHARMACEUTICALS, INC.
Reel/Frame 026337/0272 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2009
From: VICURON PHARMACEUTICALS INC.
To: NAICONS S.C.A.R.L.
Reel/Frame 022610/0099 →
Priority Claims (1)
EP 03016306 · Jul 18, 2003 · regional
Continuity (2)
Continuation In Part 1052133600
Related Publication 20050203005A1 · Sep 15, 2005